British pharma group GlaxoSmithKline (GSK) has confirmed it may buy US drug giant Pfizer’s consumer business.
GSK has also been linked to a possible acquisition of German drug-maker Merck.
Answering questions at the release of GSK’s third-quarter results yesterday, CEO Emma Walmsley admitted the possible sale of Pfizer’s $14bn consumer division was on the company’s radar.
'Looking at it'
“We are a world leader in consumer healthcare and have a demonstrated track record of successful integration, so you would expect us to look at any assets that complement our portfolio from a power brand or geographic footprint point of view,” she said.
“We would be looking at it but they only announced the process last week, so it is a little premature and it is not even confirmed for sale, to discuss in any detail if and how.